MRK
Price
$95.06
Change
-$1.37 (-1.42%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
235.92B
75 days until earnings call
Intraday BUY SELL Signals
NVO
Price
$49.02
Change
+$1.47 (+3.09%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
210.04B
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MRK vs NVO

Header iconMRK vs NVO Comparison
Open Charts MRK vs NVOBanner chart's image
Merck & Co
Price$95.06
Change-$1.37 (-1.42%)
Volume$86.78K
Capitalization235.92B
Novo-Nordisk A/S
Price$49.02
Change+$1.47 (+3.09%)
Volume$126.74K
Capitalization210.04B
MRK vs NVO Comparison Chart in %
MRK
Daily Signal:
Gain/Loss:
NVO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MRK vs. NVO commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Hold and NVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (MRK: $95.05 vs. NVO: $47.55)
Brand notoriety: MRK: Notable vs. NVO: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRK: 119% vs. NVO: 108%
Market capitalization -- MRK: $235.92B vs. NVO: $210.04B
MRK [@Pharmaceuticals: Major] is valued at $235.92B. NVO’s [@Pharmaceuticals: Major] market capitalization is $210.04B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $939.41B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $99.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRK’s FA Score shows that 2 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).

  • MRK’s FA Score: 2 green, 3 red.
  • NVO’s FA Score: 2 green, 3 red.
According to our system of comparison, MRK is a better buy in the long-term than NVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRK’s TA Score shows that 4 TA indicator(s) are bullish while NVO’s TA Score has 4 bullish TA indicator(s).

  • MRK’s TA Score: 4 bullish, 5 bearish.
  • NVO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NVO is a better buy in the short-term than MRK.

Price Growth

MRK (@Pharmaceuticals: Major) experienced а +3.94% price change this week, while NVO (@Pharmaceuticals: Major) price change was -3.26% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.05%. For the same industry, the average monthly price growth was +0.88%, and the average quarterly price growth was +16.69%.

Reported Earning Dates

MRK is expected to report earnings on Feb 03, 2026.

NVO is expected to report earnings on Feb 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-0.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($236B) has a higher market cap than NVO($210B). NVO has higher P/E ratio than MRK: NVO (13.54) vs MRK (12.57). MRK YTD gains are higher at: -1.701 vs. NVO (-41.466). NVO has higher annual earnings (EBITDA): 154B vs. MRK (25B). MRK has less debt than NVO: MRK (35.4B) vs NVO (99.3B). NVO has higher revenues than MRK: NVO (312B) vs MRK (63.6B).
MRKNVOMRK / NVO
Capitalization236B210B112%
EBITDA25B154B16%
Gain YTD-1.701-41.4664%
P/E Ratio12.5713.5493%
Revenue63.6B312B20%
Total CashN/A18.9B-
Total Debt35.4B99.3B36%
FUNDAMENTALS RATINGS
MRK vs NVO: Fundamental Ratings
MRK
NVO
OUTLOOK RATING
1..100
143
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
11
Undervalued
PROFIT vs RISK RATING
1..100
6186
SMR RATING
1..100
2615
PRICE GROWTH RATING
1..100
4584
P/E GROWTH RATING
1..100
8696
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (11) in the Pharmaceuticals Major industry is in the same range as NVO (11). This means that MRK’s stock grew similarly to NVO’s over the last 12 months.

MRK's Profit vs Risk Rating (61) in the Pharmaceuticals Major industry is in the same range as NVO (86). This means that MRK’s stock grew similarly to NVO’s over the last 12 months.

NVO's SMR Rating (15) in the Pharmaceuticals Major industry is in the same range as MRK (26). This means that NVO’s stock grew similarly to MRK’s over the last 12 months.

MRK's Price Growth Rating (45) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVO (84). This means that MRK’s stock grew somewhat faster than NVO’s over the last 12 months.

MRK's P/E Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as NVO (96). This means that MRK’s stock grew similarly to NVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRKNVO
RSI
ODDS (%)
Bearish Trend 2 days ago
54%
Bullish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 6 days ago
54%
MACD
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
47%
Bearish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 7 days ago
49%
Bullish Trend 8 days ago
68%
Declines
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 6 days ago
61%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
MRK
Daily Signal:
Gain/Loss:
NVO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HYZD22.440.03
+0.12%
WisdomTree Interest Rt Hdg Hi Yld Bd ETF
IRTR30.510.01
+0.02%
iShares LifePath Retirement ETF
INCE59.05-0.16
-0.27%
Franklin Income Equity Focus ETF
IVE205.81-0.70
-0.34%
iShares S&P 500 Value ETF
YMAX10.48-0.07
-0.66%
YieldMax Universe Fund Of Option Inc ETF

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
+3.05%
NONOF - NVO
70%
Closely correlated
+3.26%
TECH - NVO
36%
Loosely correlated
-0.57%
GMAB - NVO
35%
Loosely correlated
+0.82%
MRK - NVO
35%
Loosely correlated
-1.43%
AMGN - NVO
34%
Loosely correlated
-0.46%
More